Lantern Pharma Achieves Milestone in Phase 2 HARMONIC Trial for Non-Smoker NSCLC Patients in Japan

Lantern Pharma (NASDAQ: LTRN), a pioneer in AI-driven oncology drug development, has successfully completed the targeted enrollment for its Phase 2 HARMONIC clinical trial in Japan ahead of schedule. This trial, which focuses on never-smoker non-small cell lung cancer (NSCLC) patients who have progressed after tyrosine kinase inhibitors, has enrolled 10 patients across five sites, including the prestigious National Cancer Center Japan. The trial evaluates the efficacy of LP-300 in combination with carboplatin and pemetrexed, building on promising early U.S. data that showed an 86% clinical benefit rate, including a durable complete response lasting nearly two years.

The achievement underscores Lantern Pharma's strategic international expansion into regions with a higher prevalence of never-smoker NSCLC, such as Japan and Taiwan, where enrollment continues alongside U.S. sites. CEO Panna Sharma highlighted the milestone as a validation of the company's approach to leveraging its proprietary RADR(R) platform, which utilizes over 100 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms to accelerate drug discovery and development.

The global HARMONIC trial aims to enroll approximately 90 patients, offering a beacon of hope for a patient population with limited treatment options. Lantern Pharma's innovative use of AI and machine learning in oncology drug development not only promises to reduce costs and timelines but also has the potential to revolutionize cancer treatment. With a pipeline estimated to have a combined annual market potential of over $15 billion USD, Lantern Pharma is at the forefront of delivering life-changing therapies to cancer patients worldwide.

For more information on Lantern Pharma's groundbreaking work, visit https://ibn.fm/IcDma.